GABA-B RECEPTORS AND PARKINSON'S DISEASE
GABA-B 受体与帕金森病
基本信息
- 批准号:8357385
- 负责人:
- 金额:$ 2.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAnimalsBaclofenBrainComplementComplexCorpus striatum structureDataFundingGABA Transporter 1GABA transporterGABA-B ReceptorGAT3 transporterGlobus PallidusGrantIn VitroInjection of therapeutic agentLeadMediatingMicroinjectionsMonkeysNational Center for Research ResourcesParkinson DiseaseParkinsonian DisordersPlayPrimatesPrincipal InvestigatorRattusReceptor ActivationRegulationResearchResearch InfrastructureResourcesRoleSiteSliceSourceSynapsesTimeUnited States National Institutes of Healthcostgamma-Aminobutyric Acidinhibitor/antagonistnonhuman primatepostsynapticpresynapticresearch studyreuptaketransmission process
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
During the past funding period, efforts have been devoted towards the understanding of the role GABA transporters (GATs) may play in regulating GABA-B receptors activation in the pallidal complex of normal and parkinsonian nonhuman primates. These experiments were complemented with in vitro electrophysiological studies in rat brain slices to further understand the synaptic mechanisms by which GAT blockade modulates activity of pre- and postsynaptic GABA-B receptors in the globus pallidus. The following conclusions can be made from these studies: (1) The localization of the GABA-BR1 subunit of the GABA-B receptor in GPe and GPi was similar in parkinsonian and normal monkeys. However, the reduction in firing in GPe and GPi produced by microinjections of the GABA-B receptor agonist baclofen was larger in MPTP-treated animals than in normal monkeys, and injections of the GABA-B receptor antagonist CGP55845A produced more commonly decreased firing in GPi in the parkinsonian than in the normal animals.
In addition, the injections of baclofen in GPe and GPi, or of CGP55845A in GPi lead to a significant increase in the proportion of spikes in rebound bursts in parkinsonian animals, but not in normal monkeys. Thus, GABA-B receptor mediated transmission is altered in GPi and may contribute to bursting activities in the parkinsonian state. (2) In vitro, GAT inhibitors significantly prolonged the decay time, but did not affect the amplitude, of eIPSCs induced by striatal stimulation (15-20 volts) in the rat GP. These data indicate that GAT-1 and GAT-3 represent differential target sites through which GABA reuptake may subserve complementary regulation of GABAergic transmission in the rat GP.
这个子项目是许多利用资源的研究子项目之一
由NIH/NCRR资助的中心拨款提供。子项目的主要支持
而子项目的主要调查员可能是由其他来源提供的,
包括其它NIH来源。 列出的子项目总成本可能
代表子项目使用的中心基础设施的估计数量,
而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。
在过去的资助期间,一直致力于了解GABA转运蛋白(GATs)在调节正常和帕金森病非人灵长类动物苍白球复合体中GABA-B受体激活中可能发挥的作用。这些实验与大鼠脑切片中的体外电生理学研究相补充,以进一步了解GAT阻断调节苍白球中突触前和突触后GABA-B受体活性的突触机制。结果表明:(1)GABA-B受体GABA-BR 1亚单位在帕金森病猴和正常猴的GPe和GPi中的定位相似。然而,减少在GPe和GPi产生的GABA-B受体激动剂巴氯芬微量注射MPTP治疗的动物比在正常的猴子,和注射GABA-B受体拮抗剂CGP 55845 A产生更常见的减少在帕金森病的GPi比在正常的动物放电。
此外,巴氯芬注射GPe和GPi,或CGP 55845 A注射GPi导致帕金森病动物的反弹爆发的尖峰的比例显着增加,但在正常猴子。因此,GABA-B受体介导的传输在GPi中改变,并且可能有助于帕金森病状态中的爆发活动。(2)在体外,GAT抑制剂显著延长了大鼠GP中纹状体刺激(15-20伏)诱导的eIPSC的衰减时间,但不影响振幅。这些数据表明,GAT-1和GAT-3代表不同的目标网站,通过GABA再摄取可能subserve补充调节GABA能传输在大鼠GP。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yoland Smith其他文献
Yoland Smith的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yoland Smith', 18)}}的其他基金
Connectome of Motor Corticofugal Neurons in Parkinsonian Monkeys
帕金森猴运动皮质神经元的连接组
- 批准号:
10284849 - 财政年份:2021
- 资助金额:
$ 2.26万 - 项目类别:
Connectome of Motor Corticofugal Neurons in Parkinsonian Monkeys
帕金森猴运动皮质神经元的连接组
- 批准号:
10495224 - 财政年份:2021
- 资助金额:
$ 2.26万 - 项目类别:
Pathophysiology of the Pedunculopontine Nucleus in Parkinson's Disease
帕金森病桥脚核的病理生理学
- 批准号:
10213844 - 财政年份:2017
- 资助金额:
$ 2.26万 - 项目类别:
Pathophysiology of the Pedunculopontine Nucleus in Parkinson's Disease
帕金森病桥脚核的病理生理学
- 批准号:
9975917 - 财政年份:2017
- 资助金额:
$ 2.26万 - 项目类别:
Pathophysiology of the Pedunculopontine Nucleus in Parkinson's Disease
帕金森病桥脚核的病理生理学
- 批准号:
9404759 - 财政年份:2017
- 资助金额:
$ 2.26万 - 项目类别:
A2AR/MGLUR5 ANTAGONIST COMBINATION ANTIPARKINSONIAN THERAPY IN MPTP MONKEYS
A2AR/MGLUR5 拮抗剂联合抗帕金森病治疗 MPTP 猴
- 批准号:
8357543 - 财政年份:2011
- 资助金额:
$ 2.26万 - 项目类别:
ANATOMICAL AND PHYSIOLOGICAL CHARACTERIZATION OF THE THALAMOSTRIATAL SYSTEM
丘纹系统的解剖学和生理学特征
- 批准号:
8357545 - 财政年份:2011
- 资助金额:
$ 2.26万 - 项目类别:
EVALUATION OF PROSAVIN EFFICACY TO MPTP-LESIONED MACAQUES
PROSAVIN 对 MPTP 损伤的猕猴的功效评估
- 批准号:
8357571 - 财政年份:2011
- 资助金额:
$ 2.26万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 2.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 2.26万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 2.26万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 2.26万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 2.26万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 2.26万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 2.26万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 2.26万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 2.26万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 2.26万 - 项目类别:














{{item.name}}会员




